PARTNERING WITH INTARCIA

To maximize the commercial potential of our technology, Intarcia continues to evaluate new opportunities for novel and proprietary product candidates, with efforts focused around two areas:

  • Evaluation of new applications of our drug delivery technology to develop products for which we can hold exclusive development and commercialization rights; and
  • Exploration of collaborative opportunities with partners to which our formulation and drug delivery technology and expertise can lend enhancement of life-cycle management, product line extension or a competitive edge.

To learn more about Intarcia's partnering opportunities or accessing Intarcia's formulation and delivery technology platform, please contact Intarcia Business Development at busdev@intarcia.com.

 

Our Pipeline

Intarcia's lead product candidate, ITCA 650 is being developed for the treatment of type 2 diabetes and employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted sub-dermally to provide continuous and consistent drug therapy.


LEARN MORE